膀胱内注射苏拉明预防移行细胞癌
Intravesical suramin in the prevention of transitional cell carcinoma.
作者信息
Graham S D, Napalkov P, Oladele A, Keane T E, Petros J A, Clarke H S, Kassabian V S, Dillehay D L
机构信息
Department of Surgery, Emory University School of Medicine, Atlanta, Georgia.
出版信息
Urology. 1995 Jan;45(1):59-63. doi: 10.1016/s0090-4295(95)96720-6.
OBJECTIVES
To examine the effects of intravesical suramin on N-methyl-N-nitrosurea (MNU)-induced bladder tumors in Fischer 344 rats.
METHODS
Multiple cohorts of female rats received four biweekly intravesical instillations of MNU. A control group received no other treatment, the experimental group received 25 mg/kg intravesical suramin twice a week beginning at week 6.
RESULTS
After 18 weeks from the first instillation of MNU, 60% to 65% of control animals developed papillary transitional cell carcinoma, compared with only 0% to 10% of the suramin-treated animals (P = 0.01 to P = 0.0007). There was no local or systemic toxicity observed.
CONCLUSIONS
Intravesical suramin is an effective chemopreventative therapy for transitional cell carcinoma in vivo with minimal toxicity.
目的
研究膀胱内注射苏拉明对N-甲基-N-亚硝基脲（MNU）诱导的Fischer 344大鼠膀胱肿瘤的影响。
方法
多组雌性大鼠每两周接受4次膀胱内灌注MNU。对照组不接受其他治疗，实验组从第6周开始每周两次膀胱内注射25 mg/kg苏拉明。
结果
首次灌注MNU 18周后，60%至65%的对照动物发生乳头状移行细胞癌，而接受苏拉明治疗的动物仅为0%至10%（P = 0.01至P = 0.0007）。未观察到局部或全身毒性。
结论
膀胱内注射苏拉明是一种有效的体内预防移行细胞癌的化疗方法，毒性极小。
Zotero 插件